{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Stem+Cell+Transplantation&page=26", "query": { "intervention": "Hematopoietic Stem Cell Transplantation", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 2559, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Stem+Cell+Transplantation&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Stem+Cell+Transplantation&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:17:32.550Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00020943", "title": "Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 79, "start_date": "2001-06", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2016-07-19", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 80, "location_summary": "Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 59 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020943" }, { "nct_id": "NCT04154735", "title": "Autologous Transplant Targeted Against Crohn's", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Rifaximin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04154735" }, { "nct_id": "NCT00176917", "title": "Stem Cell Transplantation for Hurler", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucopolysaccharidosis I", "Mucopolysaccharidosis VI", "Mannosidosis", "Mucolipidosis Type II (I-cell Disease)" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Busulfan, Cyclophosphamide, ATG", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 41, "start_date": "1999-05", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176917" }, { "nct_id": "NCT01811368", "title": "Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Non Hodgkin Lymphoma", "Relapsed Non Hodgkin Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "total nodal irradiation", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE", "DRUG" ], "sponsor": "Joseph Tuscano", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "19 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2013-03-12", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-11-30", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01811368" }, { "nct_id": "NCT00278525", "title": "Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SYSTEMIC SCLERODERMA" ], "interventions": [ { "name": "standard of care", "type": "DRUG" }, { "name": "stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 19, "start_date": "2005-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-04-30", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278525" }, { "nct_id": "NCT03653247", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Plerixafor", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "BIVV003", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC" ], "sponsor": "Sangamo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 7, "start_date": "2019-03-06", "completion_date": "2025-07-17", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 5, "location_summary": "Oakland, California • Sacramento, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03653247" }, { "nct_id": "NCT00004048", "title": "Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 monoclonal antibody MN-14", "type": "RADIATION" }, { "name": "yttrium Y 90 monoclonal antibody MN-14", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 30, "start_date": "1998-09", "completion_date": "2002-05", "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 2, "location_summary": "Belleville, New Jersey • Paterson, New Jersey", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Paterson", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004048" }, { "nct_id": "NCT00006390", "title": "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "2001-07-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 14, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 8 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006390" }, { "nct_id": "NCT02797470", "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Plasmablastic Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Follicular Lymphoma", "Stage III Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-06-23", "completion_date": "2036-03", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 4, "location_summary": "La Jolla, California • Sacramento, California • San Francisco, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02797470" }, { "nct_id": "NCT00434629", "title": "Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bexxar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2007-02", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2016-08-17", "last_synced_at": "2026-10-15T12:17:32.550Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00434629" } ] }